Transine Therapeutics Closes £13.7M in Seed Funding Transine Therapeutics, a Cambridge, UK-based biotechnology company, raised £13.7M in Seed funding.
Epidarex Capital was the lead and Dementia Discovery Fund participated in the round. Mary Canning, Principal at Epidarex Capital, has joined Transine’s Board following this financing. The company intends to use the funds to further exploit its SINEUP® platform and accelerate the development of its product portfolio, building on recent advances with its lead programs in Central Nervous System and Ophthalmology indications with key in vivo data expected this year. Founded by Professor Piero Carninci and Professor Stefano Gustincich, pioneers in functional genomics and lncRNA, and based in Cambridge, UK, and led by CEO Dr Jan Thirkettle, Transine Therapeutics is an RNA platform company developing a novel class of therapeutic RNAs (SINEUPs) capable of upregulating protein expression with a level of control and specificity across a high range of diseases and applications. Their SINEUP platform was designed to increase the expression of nearly any target protein by binding to the mRNA that encodes them and enhancing their translation. This allows us to treat diseases previously unaffected by small molecules, conventional biologics, or gene therapies.